Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCN2B8)

Drug Name
TMB-8 Drug Info
Synonyms
TMB-8; 8-(Diethylamino)octyl 3,4,5-trimethoxybenzoate; TMB 8; 57818-92-5; TM-8; 8-(N,N-Diethylamino)octyl-3,4,5-trimethoxybenzoate; 3,4,5-Trimethoxybenzoic acid, 8-(diethylamino)octyl ester; C22H37NO5; AC1L1KGS; AC1Q67GP; Lopac-861804; Lopac0_000022; BSPBio_001503; GTPL4323; CHEMBL258764; SCHEMBL2173737; CTK5A7496; DTXSID70206532; CHEBI:107633; HMS1989L05; HMS1791L05; HMS3402L05; 53464-72-5 (hydrochloride); ZINC3875139; EI-110; AKOS030559942; MCULE-5343453436; CCG-204118; NCGC00162047-03; NCGC00162047-01; NCGC00014998-06
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5494
ChEBI ID
CHEBI:107633
CAS Number
CAS 57818-92-5
TTD Drug ID
DMCN2B8

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting 5-HT 3A receptor (HTR3A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dolasetron DMMG26Z Nausea MD90 Approved [3]
Alosetron DML2A03 Diarrhea-predominant irritable bowel syndrome DD91.01 Approved [4]
Tropisetron DMNSJ7V Fibromyalgia MG30.01 Approved [5]
Palonosetron DMBHMOX Nausea MD90 Approved [6]
Levetiracetam DMTGDN8 Epilepsy 8A60-8A68 Approved [5]
Procaine DM4LSNE Anaesthesia 9A78.6 Approved [7]
Cilansetron DMP0NGX Irritable bowel syndrome DD91.0 Phase 3 [8]
BEMESETRON DMSPJX9 N. A. N. A. Discontinued in Phase 3 [9]
Norcisapride DMJSKUI Gastroesophageal reflux disease DA22.Z Discontinued in Phase 2 [10]
YM-114 DML2IXO Nausea MD90 Discontinued in Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 3A receptor (HTR3A) TTPC4TU 5HT3A_HUMAN Blocker (channel blocker) [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4323).
2 Characterization of interaction of 3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester with Torpedo californica nicotinic acetylcholine receptor and 5-hydroxytryptamine3 receptor. J Pharmacol Exp Ther. 1999 Jul;290(1):129-35.
3 Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, do... Lancet Oncol. 2009 Feb;10(2):115-24.
4 Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009 Jul;104(7):1831-43; quiz 1844.
5 Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
6 Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag. 2009 Feb;5(1):21-34.
7 Local anesthetics have different mechanisms and sites of action at recombinant 5-HT3 receptors. Reg Anesth Pain Med. 2007 Nov-Dec;32(6):462-70.
8 Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.Expert Opin Investig Drugs.2005 Feb;14(2):185-93.
9 Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships. J Med Chem. 1992 Jan 24;35(2):310-9.
10 mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I). Bioorg Med Chem Lett. 2009 Oct 1;19(19):5679-83.
11 Effect of serotonin (5-HT)3-receptor antagonists YM060, YM114 (KAE-393), ondansetron and granisetron on 5-HT4 receptors and gastric emptying in rodents. Jpn J Pharmacol. 1995 Nov;69(3):205-14.